



## Genomic Health Innovations

Luncheon/Webcast of June 6, 2013 at the Yale Club in New York

### Abstract

- Are genomic medicine innovations finally having an impact on all of us?
- Is the convergence of biology, medicine, chemistry and big data analysis transforming new standards of medical care?
- What does the future of this healthcare and life science revolution hold?

Genomic Medicine Innovations are rapidly reaching the healthcare market place and changing the way how diseases are diagnosed and treated. Advancements in our understanding of basic human biology, medicine, chemistry, instrumentation and technology to analyze big data sets are converging to redefine how diseases are diagnosed, managed and treated. A series of entrepreneurial health and life science companies are developing solutions to help manage more valuable outcomes for patients, providers and payors alike. Join us and a panel of experts and gain unique insights on the disruptive opportunities of this revolutionary advance in life science and human health.

### Panel

*Piraye Yurttas Beim*, PhD, Founder and Chief Executive Officer, Celmatix

*Harry A. Glorikian*, Managing Director, Strategy, Precision for Medicine

*Mark Monane, MD*, Chief Medical Officer, CardioDx

*Paul Pospisil, PhD*, Senior Client Partner at Korn/Ferry International

*Nathan Tinker, PhD*, Executive Director, New York Biotechnology Association (NYBA)

### Biographies



**Dr. Piraye Yurttas Beim**, is the founder and CEO of Celmatix, a New York City based entrepreneurial company that is developing diagnostic tools to improve reproductive health outcomes for female infertility. By partnering with fertility clinics, we are discovering predictive genetic biomarkers that clarify idiopathic infertility and flag premature menopause risk. Our offerings will help physicians interpret data, clarify causes of treatment failure, and optimize treatment strategies to improve success rates. Dr. Beim is one of a handful of experts in the genetics of female fertility. Her postdoctoral work (Gurdon Institute, University of Cambridge, England) is in mammalian pre-implantation embryology and her doctoral work (Cornell University, Weill Medical College/Sloan Kettering Institute, NYC) focused on the molecular and genetic underpinnings of mammalian infertility. Dr. Beim holds a BA in Plan II Honors, an elite multidisciplinary honors program, and a BS in Biology from the University of Texas at Austin.



**Mr. Harry A. Glorikian** has been Managing Director of Strategy and Personalized Medicine at Precision for Medicine, Inc. since joining in December 2012. Mr. Glorikian has more than 20 years of experience in the health care and life science industries. He has deep commercial background in diagnostics, molecular biology, proteomics, cellular biology, and biodefense. His unique understanding of technologies has shaped a sophisticated framework and proprietary analytic tools. Prior to Precision...

Platinum Sponsor

**Mexichem**

Gold Sponsor



**HOULIHAN LOKEY**

Co-Sponsor



Media Partners

**NYC Medtech**  
NYC Medical Technology forum



### Event Schedule

#### Location:

Yale Club  
50 Vanderbilt Ave., NYC  
(near Grand Central Station)

#### Event Times: (EDT)

11:15 am - 12:00 noon  
Registration and  
Networking

12:00 noon - 1:00 pm  
Luncheon

1:00 pm - 2:15 pm  
Presentation & Webcast

#### Luncheon Fees (\*):

\$90 for Non-members  
\$70 for 2011 members  
of CM&E, CPPA.

**Webcast (\*)** : \$30.

(\*) Register and check for  
Early-bird discounts at:

## Biographies (continued)

...Mr. Glorikian founded Scientia Advisors, and serves as its Managing Partner. He served at TSG Partners, Applera's Applied Biosystems, Signet Laboratories. He is Co-Founder of X-Cell Laboratories. He has been a Director of GeneNews Limited since May 2008. Mr. Glorikian has addressed the NIH, Molecular Medicine Tri-Conference and other audiences. He has authored numerous articles, appeared on CBS Evening News and been quoted by Dow Jones, Los Angeles Times, Medical Device Daily, Science Magazine, and other media outlets. He has patents in the U.S. and abroad. He holds an MBA (Boston U.), and a BA, General Biology (San Francisco State University).



**Mark Monane** is Chief Medical Officer at CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Prior to joining CardioDx, he served 11 years as managing director of equity research for Needham & Company, where he focused on analyses of emerging biotechnology companies in the cardiovascular and cancer disease areas. Prior to Needham & Company, Mark served as Senior Director of Medical Policy and Practices at Medco Health. Before joining Medco, he was an assistant professor at Harvard Medical School and the Harvard School of Public Health, where he completed fellowship training in geriatrics, clinical pharmacology, and clinical effectiveness. Mark holds an A.B. and an M.B.A. from Columbia University, an M.S. in health policy from Harvard University, and an M.D. from NYU.



**Paul Pospisil, Ph.D.**, is Senior Client Partner at Korn/Ferry International, where he recruits for positions such as chief executive officer, chief business officer, head of research and development and other key positions. With over fifteen years in the industry as a successful executive and investor, Mr. Pospisil brings a thoughtful perspective to executive search, shaped by a breadth of experiences in new product development, business development, M&A, financings, strategy, company building, operational leadership and board functions from start-up, growth to mature biotechnology and biopharmaceutical companies. Prior to joining Korn/Ferry, Mr. Pospisil was a co-founder and managing partner of Aduro Capital LLC. Previously, he was a partner in life science investments at Atlas Venture and earlier was director, strategy leadership at Millennium Pharmaceuticals. Paul holds a Ph.D. in organic chemistry from Harvard University and a bachelor's degree in biochemistry from NYU.



**Nathan Tinker, Ph.D.**, is Executive Director of the New York Biotechnology Association (NYBA), the statewide trade association representing New York's bioscience community. He serves as a spokesman and advocate for the state's industry. NYBA supports the development and growth of New York State's biotechnology industry, and serves its members and the biotechnology community by providing a network for information exchange, shared services, and collective action. He is a member of the Executive Pharmaceutical Advisory Board at Physicians Interactive. He participated in the Governor's task force on Diversifying the NY State Economy through Industry-Higher Education Partnerships. Previously, he was Executive Director at the Sabin Vaccine Institute and Founder and Executive Vice President at NanoBusiness Alliance. He holds a PhD from Fordham University, an M.A. from Georgetown University and has a degree in English from Gonzaga University.

## About CM&E

Chemical Marketing & Economics is a topical group of the American Chemical Society (ACS) NY Section. ACS, founded in 1876, is the world's largest scientific society with over 160,000 members.

CM&E organizes monthly luncheons and webcasts in New York City where industry leaders present original research and cutting-edge outlooks on business, economy, and technology in energy, materials & life science.

The American Chemical Society's NY Section was the first group in ACS to give a National Prize. Since 1903 the Annual Nichols Award of ACS NY section has been given to 108 scientists, 16 of them have received a Nobel Prize in Chemistry.

## 2013 CM&E Board

### Chair

George Rodriguez

### Program Chair

James M. Weatherall

### Secretary

Norm Klein

### Treasurer

Fred H. Siemer

### Assistant Treasurer

Karin Bartels

### Directors

Charles Brumlik

Neil Burns

Chris Cerimele

David J. Deutsch

Rhoda Kriesel

Brian Orkin

Paul Pospisil

Rick Templeton

### Associate Directors

David Ferber

Jake Zhu